Cancer Immunotherapy Market by Product (Cell Therapies, Checkpoint Inhibitors, Immunomodulators), Function (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-User - Global Forecast 2023-2030
The Cancer Immunotherapy Market is projected to reach USD 107.11 billion by 2030 from USD 69.63 billion in 2022, at a CAGR of 5.53% during the forecast period.
Market Segmentation & Coverage:This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Cancer Immunotherapy Market.
- Based on Product, market is studied across Cell Therapies, Checkpoint Inhibitors, Immunomodulators, Monoclonal Antibodies, and Vaccines. The Cell Therapies is further studied across Chimeric Antigen Receptor T Cell Therapy and Dendritic Cells. The Checkpoint Inhibitors is further studied across Cytotoxic T-Lymphocyte-Associated Protein-4 and Programmed Death 1 & Programmed Death Ligand 1. The Immunomodulators is further studied across Granulocyte-Macrophage Colony-Stimulating Factor, Interferons, Interleukins, and Oncolytic Virus. The Monoclonal Antibodies is further studied across Bispecific Monoclonal Antibodies, Conjugated Monoclonal Antibodies, and Naked Monoclonal Antibodies. The Vaccines is further studied across Prophylactic Vaccines and Therapeutic Vaccines. The Immunomodulators is projected to witness significant market share during forecast period.
- Based on Function, market is studied across Breast Cancer, Colorectal Cancer, Head & Neck Cancer, Lung Cancer, Melanoma, Multiple Myeloma, and Prostate Cancer. The Multiple Myeloma is projected to witness significant market share during forecast period.
- Based on End-User, market is studied across Cancer Research Institutes, Clinics, and Hospitals. The Hospitals is projected to witness significant market share during forecast period.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.
Market Statistics:The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.
FPNV Positioning Matrix:The FPNV Positioning Matrix is an indispensable tool for assessing the Cancer Immunotherapy Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.
Market Share Analysis:The Market Share Analysis offers invaluable insights into the vendor landscape Cancer Immunotherapy Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.
Key Company Profiles:The report delves into recent significant developments in the Cancer Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca PLC, Avid Bioservices, Inc., Bayer AG, Bristol-Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, ELI Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GSK PLC, Janssen Global Services, LLC, Merck & Co., Inc., Novartis International AG, OSE Immunotherapeutics SA, and Pfizer, Inc..
The report offers valuable insights on the following aspects:- Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
- Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
- Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
- Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
- Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:- What is the market size and forecast for the Cancer Immunotherapy Market?
- Which products, segments, applications, and areas hold the highest investment potential in the Cancer Immunotherapy Market?
- What is the competitive strategic window for identifying opportunities in the Cancer Immunotherapy Market?
- What are the latest technology trends and regulatory frameworks in the Cancer Immunotherapy Market?
- What is the market share of the leading vendors in the Cancer Immunotherapy Market?
- Which modes and strategic moves are suitable for entering the Cancer Immunotherapy Market?
Note: PDF & Excel + Online Access - 1 Year